Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which led to significant financial losses for investors [2][5]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in aTyr between January 16, 2025, and September 12, 2025, to discuss their legal options [1]. - There is a deadline of December 8, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against aTyr [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against aTyr - The complaint alleges that aTyr and its executives violated federal securities laws by making false and misleading statements about Efzofitimod, particularly regarding its ability to allow patients to taper off steroids completely [5]. - In the EFZO-FIT study, efzofitimod showed no significant change in mean daily oral corticosteroid dose at week 48, with a reduction of 2.79 mg for the drug compared to 3.52 mg for placebo [6]. - Following the release of the study results, aTyr's stock plummeted by 83.25%, dropping from $6.03 to $1.01 [6].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in aTyr between January 16, 2025 and September 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - November 10, 2025 ...

Core Insights - aTyr Pharma, Inc. is a clinical stage biotechnology company focused on developing first-in-class medicines from its proprietary tRNA synthetase platform [1][3] - The company will present at the Piper Sandler 37 Annual Healthcare Conference on December 2, 2025, in New York, NY [1][2] Company Overview - aTyr leverages evolutionary intelligence to translate tRNA synthetase biology into new therapies targeting fibrosis and inflammation [3] - The company's lead therapeutic candidate, efzofitimod, is an immunomodulator in clinical development for treating interstitial lung disease, which involves immune-mediated disorders causing lung inflammation and progressive fibrosis [3]

Results reported for Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Company plans to meet with the FDA to determine path forward for efzofitimod in pulmonary sarcoidosis in the first quarter of 2026.  Company expects to complete enrollment in Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) in the first half of 2026. Ended the third quarter 2025 with $92.9 million in cash, cash equivalents, restricted cash and investments. SAN DIE ...

Core Viewpoint - aTyr Pharma, Inc. is facing a class action lawsuit from investors who purchased securities during the specified class period, following the announcement of disappointing clinical trial results [1][3]. Group 1: Legal Action - The Portnoy Law Firm is advising aTyr Pharma investors regarding a class action lawsuit for those who bought securities between January 16, 2025, and September 12, 2025 [1]. - Investors have until December 8, 2025, to file a lead plaintiff motion in the class action [1]. Group 2: Clinical Trial Results - On September 15, 2025, aTyr announced topline results from the Phase 3 EFZO-FIT™ study involving 268 patients with pulmonary sarcoidosis, which failed to meet its primary endpoint [3]. - Following the announcement of the trial results, aTyr's stock price experienced a significant decline during intraday trading on the same day [3]. Group 3: Investor Support - The Portnoy Law Firm offers complimentary case evaluations for investors to discuss their legal rights and options for recovering losses [2]. - The firm has a history of recovering over $5.5 billion for investors affected by corporate wrongdoing [4].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in aTyr between January 16, 2025 and September 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Faruqi & ...

Core Viewpoint - aTyr Pharma, Inc. experienced a dramatic decline in share price, dropping over 80% after failing to meet the primary endpoint in its late-stage study of efzofitimod for pulmonary sarcoidosis treatment [1][7]. Company Summary - On September 15, 2025, aTyr announced that its EFZO-FIT trial did not achieve statistical significance in steroid reduction after a year of tapering, leading to a significant market reaction [7]. - The company had previously assured investors that its Phase 2 data was among the best seen by experts and highlighted a multi-billion-dollar market opportunity for efzofitimod [6]. Investigation Summary - Following the market reaction, Hagens Berman, a national shareholders rights firm, initiated an investigation into whether aTyr misled investors regarding its Phase 2 data and Phase 3 trial design [2][5]. - The investigation is focused on the accuracy of aTyr's disclosures about the quality of its Phase 2 data and the design of the EFZO-FIT trial [5]. Market Reaction - The announcement of the topline results led to a flood of analyst downgrades and a catastrophic drop in aTyr's share price, reflecting investor disappointment and loss of confidence [7].

Core Insights - The Phase 3 EFZO-FIT™ study of efzofitimod demonstrated clinical benefits in patients with pulmonary sarcoidosis, particularly in improving fatigue and general health scores at week 48 compared to placebo [2][3][4] - Despite not meeting the primary endpoint of reducing mean daily oral corticosteroid dose, efzofitimod showed potential to improve multiple disease-related health outcomes, including cough, shortness of breath, and fatigue [3][4] Company Overview - aTyr Pharma, Inc. is a clinical stage biotechnology company focused on developing first-in-class medicines from its proprietary tRNA synthetase platform [2][9] - The company is investigating efzofitimod, a biologic immunomodulator, for treating interstitial lung disease (ILD), which includes pulmonary sarcoidosis and systemic sclerosis-related ILD [8][9] Study Findings - The study involved 268 patients and presented significant improvements in the Fatigue Assessment Scale Total Score (p=0.0226) and King's Sarcoidosis Questionnaire-General Health score (p=0.0197) for the 5.0 mg/kg efzofitimod treatment group [2][3][4] - Additional outcomes included a trend towards a greater proportion of patients achieving steroid-free status for at least six months and improvements in KSQ-Lung score [3][4] Treatment Context - Pulmonary sarcoidosis affects approximately 200,000 Americans, with current treatments primarily involving corticosteroids, which have limited efficacy and significant side effects [6][7] - Efzofitimod aims to provide a safer and more effective treatment option for patients with pulmonary sarcoidosis, potentially reducing reliance on chronic steroids [3][8]

Core Insights - aTyr Pharma, Inc. experienced a significant drop in share price, over 80%, following the announcement that its late-stage study of efzofitimod for pulmonary sarcoidosis did not meet its primary endpoint [1][5] Company Developments - The company reported that the topline results of the EFZO-FIT trial failed to achieve statistical significance in steroid reduction after a year of forced tapering, with placebo tapering outperforming the company's projections [5] - aTyr had previously assured investors that its Phase 2 data was among the best seen by experts and emphasized a multi-billion-dollar market opportunity for efzofitimod [4] Market Reaction - Following the disappointing trial results, the market reacted sharply, leading to a significant decline in aTyr's share price and prompting numerous analyst downgrades [5] Legal Investigation - Hagens Berman, a national shareholders rights firm, has initiated an investigation into whether aTyr misled investors regarding the Phase 2 data and the design of the Phase 3 EFZO-FIT trial [2][6] - The firm is encouraging investors who suffered losses to come forward and is seeking information from individuals who may assist in the investigation [2][6]

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether aTyr and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On September 15, 2 ...